Cergentis has now become a member of the National Institute of Standards and Technology (NIST) Genome Editing consortium! This organization brings together leading experts across industry and academia in the genome editing fields.
Over the years, the incredible advancements in targeted genome editing have unlocked new research opportunities to better study gene function and combat diseases. The NIST Genome Editing Consortium aims to:
- Put in place a unified reference set of terms and technical definition for genome editing studies
- Evaluate genome editing assay pipelines
- Develop benchmarks materials
- Generate benchmark data
- Develop suggested minimal information reporting for public studies
With these goals, members of NIST hope to clarify scientific communication - in terms of data interpretation and reporting - and to mitigate risks when using genome editing technologies in research and commercial products.
“Cergentis’ contribution to the NIST Genome Editing Consortium reflects a shared commitment to improve the quality of genetic research worldwide.”
said Joris Schuurmans, CEO of Cergentis. As a proud collaborator, Cergentis hopes that this new and global cooperative - in helping address regulatory and measurement challenges for regenerative medicine products and advanced therapies - will help to better serve the entire biotechnology community in the long run and to further accelerate scientific discoveries.
Cergentis is a privately held genomics company and has developed and patented the Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of advanced genetic engineering.
With its TLA-based solutions, Cergentis has established itself as the go-to partner for the complete, robust and rapid genetic characterization of genetically engineered cell lines, cell and gene therapy products and transgenic (animal) models for the global biopharmaceutical industry as well as leading research institutes worldwide. We develop and sell kits and services for targeted and complete sequencing of (trans)genes and gene editing events and provide services to support R&D in these fields.